Findimmune
Findimmune is a France-based company developing anticancer and immune therapies, focusing on immune stimulation for anticancer vaccination and converting 'cold' tumors into 'hot' tumors. It benefits from a drug discovery platform in partnership with Gustave Roussy Cancer Campus, focusing on macrophage immune checkpoints. The company aims to identify and develop new drugs to benefit patients suffering from cancer and immune system diseases, emphasizing disruptive science and innovative therapeutic development.
Industries
Nr. of Employees
small (1-50)
Findimmune
Institut Gustave Roussy 39 Rue Camille Desmoulins 94800 Villejuif
Products
F1902
A preactivated oxazaphosphorine derivative designed to release active drug without producing a specified toxic metabolite; demonstrates >90% release in active form, in vivo anti-tumor activity by cytotoxic or immunomodulatory mechanisms, synergizes with PD-1 pathway inhibitors, and forms self-nano-assemblies for improved biodistribution and targeting.
F2001
Therapeutic candidate that modulates a macrophage immune checkpoint to reprogram pro-inflammatory alveolar macrophages toward an anti-inflammatory phenotype for the management of cytokine storm in ARDS.
F1901
Pipeline candidate listed by the organization; specific public details not provided on the referenced pages.
F1902
A preactivated oxazaphosphorine derivative designed to release active drug without producing a specified toxic metabolite; demonstrates >90% release in active form, in vivo anti-tumor activity by cytotoxic or immunomodulatory mechanisms, synergizes with PD-1 pathway inhibitors, and forms self-nano-assemblies for improved biodistribution and targeting.
F2001
Therapeutic candidate that modulates a macrophage immune checkpoint to reprogram pro-inflammatory alveolar macrophages toward an anti-inflammatory phenotype for the management of cytokine storm in ARDS.
F1901
Pipeline candidate listed by the organization; specific public details not provided on the referenced pages.
Services
Design and execution of a proof-of-concept intratumoral study in dogs with oral melanoma or squamous cell carcinoma, including recruitment criteria, dosing schedule (3 injections at D1, D30, D90), general anaesthesia procedures, and efficacy assessment by iRECIST.
Collaborative discovery and early development platform operating in partnership with an academic cancer campus and an INSERM research unit to support drug discovery, translational research and preclinical development.
Design and execution of a proof-of-concept intratumoral study in dogs with oral melanoma or squamous cell carcinoma, including recruitment criteria, dosing schedule (3 injections at D1, D30, D90), general anaesthesia procedures, and efficacy assessment by iRECIST.
Collaborative discovery and early development platform operating in partnership with an academic cancer campus and an INSERM research unit to support drug discovery, translational research and preclinical development.
Expertise Areas
- Macrophage reprogramming and innate immune modulation
- Immuno-oncology therapeutic development
- Nanomedicine and targeted drug delivery
- Molecular radiotherapy
Key Technologies
- Macrophage immune checkpoint modulation
- Self-assembling nanoformulations
- Preactivated prodrug chemistry
- Aptamer- and peptide-mediated targeting
News & Updates
Safety and efficacy of F1901 by intra-tumoral administration in dogs With oral malignant tumor: a prOOF of concept study
Findimmune researchers have designed novel patented formulations allowing tumour cell specific targeting. The company is developing F1902, an oxazaphosphorine derivative that avoids the toxic metabolic pathway, with proven in-vivo anti-tumoral activity and synergic effects with anti-PD1 monoclonal antibodies.
Findimmune's research platform is dedicated to filling its pipeline with biotherapies, new chemical entities, and repurposed molecules, discovered and developed using expertise in molecular radiotherapy, macrophage programming, drug delivery, and nano-medicine.
Safety and efficacy of F1901 by intra-tumoral administration in dogs With oral malignant tumor: a prOOF of concept study
Findimmune researchers have designed novel patented formulations allowing tumour cell specific targeting. The company is developing F1902, an oxazaphosphorine derivative that avoids the toxic metabolic pathway, with proven in-vivo anti-tumoral activity and synergic effects with anti-PD1 monoclonal antibodies.
Findimmune's research platform is dedicated to filling its pipeline with biotherapies, new chemical entities, and repurposed molecules, discovered and developed using expertise in molecular radiotherapy, macrophage programming, drug delivery, and nano-medicine.